Abstract:BACKGROUND: Troglitazone is a new insulin-sensitizing agent used to treat type 2 diabetes mellitus. The mechanism by which troglitazone exerts its effect on systemic glucose metabolism is unknown.OBJECTIVE: To determine the effects of 6 months of troglitazone monotherapy on glucose metabolism in patients with type 2 diabetes mellitus.DESIGN: Randomized, double-blind, placebo-controlled trial.SETTING: Six general clinical research centers at university hospitals.PATIENTS: 93 patients (mean age, 52 years) with type 2 diabetes mellitus (mean fasting plasma glucose level, 11.2 mmol/L) who were being treated with diet alone or who had discontinued oral antidiabetic medication therapy.INTERVENTION: Patients were randomly assigned to one of five treatment groups (100, 200, 400, or 600 mg of troglitazone daily or placebo) and had metabolic assessment before and after 6 months of treatment.MEASUREMENTS: Plasma glucose and insulin profiles during a meal tolerance test; basal hepatic glucose production and insulin-stimulated glucose disposal rate during a hyperinsulinemic-euglycemic clamp procedure.RESULTS: Troglitazone at 400 and 600 mg/d decreased both fasting (P < 0.001) and postprandial (P = 0.016) plasma glucose levels by approximately 20%. All four troglitazone dosages also decreased fasting (P = 0.012) and postprandial (P < 0.001) triglyceride levels; 600 mg of the drug per day decreased fasting free fatty acid levels (P = 0.018). Plasma insulin levels decreased in the 200-, 400-, and 600-mg/d groups (P < 0.001), and C-peptide levels decreased in all five study groups (P < 0.001). Basal hepatic glucose production was suppressed in the 600-mg/d group compared with the placebo group (P = 0.02). Troglitazone at 400 and 600 mg/d increased glucose disposal rate by approximately 45% above pretreatment levels (P = 0.003). Stepwise regression analysis showed that troglitazone therapy was the strongest predictor of a decrease in fasting (P < 0.001) or postprandial (P = 0.01) glucose levels. Fasting C-peptide level was the next strongest predictor (higher C-peptide level equaled greater glucose-lowering effect).CONCLUSION: Troglitazone monotherapy decreased fasting and postprandial glucose levels in patients with type 2 diabetes, primarily by augmenting insulin-mediated glucose disposal.

Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells.

Acute exposure of beta-cells to troglitazone decreases insulin hypersecretion via activating AMPK.

Effect of Troglitazone on Insulin Secretion in Pancreatic Β-Cells and Its Mechanism

Berberine acutely inhibits insulin secretion from β-cells through 3′,5′-cyclic adenosine 5′-monophosphate signaling pathway

Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus

Troglitazone action is independent of adipose tissue.

Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic βTC-6 cells -1mTORβTC-6.

Glucagon-Like Peptide-1 Analog-Mediated Protection Against Cholesterol-Induced Apoptosis Via Mammalian Target Of Rapamycin Activation In Pancreatic Beta Tc-6 Cells

Autophagy augmented by troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling.

Palmitate activates AMP-activated protein kinase and regulates insulin secretion from β cells

Glucotoxicity and Α Cell Dysfunction: Involvement of the PI3K/Akt Pathway in Glucose-Induced Insulin Resistance in Rat Islets and Clonal Αtc1-6 Cells.

Troglitazone Inhibits Cell Proliferation by Attenuation of Epidermal Growth Factor Receptor Signaling Independent of Peroxisome Proliferator-Activated Receptor Γ

Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes

Metformin Activates AMPK and Inhibits Insulin Secretion in MIN6 Cell Line Culture

Berberine Inhibits Glucose Oxidation and Insulin Secretion in Rat Islets.

Glucose Potentiates Beta-Cell Function by Inducing Tph1 Expression in Rat Islets

Pioglitazone lowers serum retinol binding protein 4 by suppressing its expression in adipose tissue of obese rats.

[Inhibitory Effects of Thiazolidinedione Upon Cytokine-Induced Apoptosis in Pancreatic Beta-Cell Line].

Glucagon-Like Skin-1’s Effect on Islet β Cells in High Glucose via AMPK/mTOR Pathway

Pioglitazone Inhibits the Expression of Nicotinamide Adenine Dinucleotide Phosphate Oxidase and P38 Mitogen-Activated Protein Kinase in Rat Mesangial Cells

Troglitazone Enhances the Hepatotoxicity of Acetaminophen by Inducing CYP3A in Rats